IP Library Granted Patent US 7,267,821
Granted Patent B2
US 7,267,821 · App. 10/476,233 · Granted Sep 11, 2007

Binding member which binds to both Lewis

Assignee: Scancell Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,267,821
App. No.
10/476,233
Granted
Sep 11, 2007
Kind
B2
Abstract

The invention relates to the use of a binding member which binds to Lewis y and Lewis b haptens in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to Lewis y and Lewis b haptens and cancer cells and induces cells death.

Claims (7)

1. A method of treatment of a tumor in a patient, comprising administering to the patient an effective amount of a naked antibody or fragment thereof, which antibody or fragment thereof binds to both Lewis y and Lewis b haptens and does not bind to H blood group antigen and comprises a constant region of human antibody class IgM, IgA, IgG 2 or IgG 3 , and which antibody comprises the CDRs of the antibody produced by the cell line deposited as ECACC Accession No. 01050118.

2. The method of claim 1 , wherein the antibody is produced by the cell line deposited as ECACC Accession No. 01050118.

3. The method of claim 1 , wherein the antibody or fragment thereof binds to both Lewis y and Lewis b haptens in extended form, wherein the extended forms are:

4. A method of treating a patient comprising administering to the patient an effective amount of a naked antibody or fragment thereof, which antibody or fragment thereof binds to both Lewis y and Lewis b haptens and does not bind to H blood group antigen and comprises a constant region of human antibody class IgM, IgA, IgG 2 or IgG 3 , and which antibody comprises CDRs of the antibody produced by the cell line deposited as ECACC Accession No. 01050118 wherein the patient has leukemia.

5. The method of claim 1 , wherein the cancer is one or more of colorectal, breast, ovarian, gastric, lung, liver, skin, and myeloid cancer.

6. The method of claim 1 , wherein the patient is a mammal.

7. The method of claim 6 , wherein the patient is a human.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECTION OF THE ASSIGNEE ADDRESS TO REMOVE "RON KAL" FROM THE ADDRESS PREVIOUSLY RECORDED ON REEL 031485 FRAME 0784. ASSIGNOR(S) HEREBY CONFIRMS THE NAME CHANGE FROM CEPHALON AUSTRALIA PTY LTD TO TEVA PHARMACEUTICALS AUSTRALIA PTY. Recorded Feb 24, 2014
From: CEPHALON AUSTRALIA PTY LTD
To: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Reel/Frame 032403/0896 →
CHANGE OF NAME Recorded Oct 24, 2013
From: CEPHALON AUSTRALIA PTY LTD
To: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Reel/Frame 031485/0784 →
CHANGE OF NAME Recorded Sep 2, 2010
From: ARANA THERAPEUTICS PTY LTD
To: CEPHALON AUSTRALIA PTY LTD
Reel/Frame 024927/0781 →
CHANGE OF NAME Recorded Sep 1, 2010
From: ARANA THERAPEUTICS LIMITED
To: ARANA THERAPEUTICS PTY LTD
Reel/Frame 024915/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2008
From: SCANCELL LIMITED
To: ARANA THERAPEUTICS LIMITED
Reel/Frame 020753/0321 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2004
From: DURRANT, LINDA G.; PARSONS, TINA
To: SCANCELL LIMITED
Reel/Frame 015338/0901 →
Priority Claims (1)
GB 0111628.4 · May 11, 2001 · national
Continuity (1)
Related Publication 20040185052A1 · Sep 23, 2004